Major Depressive Disorder

Latest News

sleepy somnolence
Treatment Comparison: Somnolence/Sedation With Dopamine Partial Agonists vs D2 Receptor Antagonists

May 29th 2025

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

MAOIs
Understanding and Overcoming Negative Preconceptions About MAOIs

May 29th 2025

anhedonia
New Data: Cariprazine Adjunctive to Antidepressant Therapy for Anhedonia Symptoms

May 29th 2025

Study Finds Zuranolone Effective for Anhedonia in Patients With PPD
Study Finds Zuranolone Effective for Anhedonia in Patients With PPD

May 20th 2025

money
The Double-Edged Sword of Affluence

May 12th 2025

Latest CME Events & Activities

Expert Perspectives in the Recognition and Management of Postpartum Depression

View More

Southern California Psychiatry Conference

July 11-12, 2025

Register Now!

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

View More

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

View More

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

View More

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

View More

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

View More

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

View More

Southern Florida Psychiatry Conference

November 21-22, 2025

Register Now!

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

View More

Optimizing Care for Patients With Tardive Dyskinesia

View More

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

View More

More News

© 2025 MJH Life Sciences

All rights reserved.